{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:16:04Z","timestamp":1781295364948,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shire International GmbH","award":["IIR-GBR-000133"],"award-info":[{"award-number":["IIR-GBR-000133"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The mucopolysaccharidoses are a group of rare, inherited metabolic disorders. MPS II is a X-linked recessive disease, also known as Hunter syndrome. Clinical manifestations include upper and lower respiratory tract, and head and neck pathologies influencing quality of life, morbidity, and mortality. Medical and surgical intervention outcomes for MPS are reported inconsistently, creating a challenge when synthesising and contrasting evidence. This study set out to address the inconsistency in outcome measurement in this field. International recommendations for developing a core outcome set were adopted. Available data from qualitative studies and outcomes from a modified e-Delphi surveys were used to develop a list of candidate outcomes for consideration. Three consensus meetings with patients diagnosed with MPS II alongside their parents\/carers were ran to help finalise a list of outcome domains.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Survival, airway obstruction, and quality of life were outcomes identified as important to always measure in all MPS II clinical trials and\/or in clinical practice. Other outcomes for younger children included swallowing difficulties, cognitive development, ability to participate in education, and communication. The adolescent group included safety of chewing and swallowing, complications of anaesthesia, sleep quality and apnoea, nasal problems, and chronic otitis media. The adult group identified sleep apnoea, and hearing, as additional outcomes to measure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A novel methodology for determining a core outcome set in rare diseases has been recommended. Both functional and quality of life outcomes were identified by the three age groups of individuals and\/or their parents. Adoption of these sets of outcomes in future clinical trials and\/or clinical practice will enable comparison of outcomes reported.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03581-y","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T21:08:41Z","timestamp":1740604121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prioritisation of head, neck, and respiratory outcomes in mucopolysaccharidosis type II: lessons from a rare disease consensus exercise and comparison of parental and clinical priorities"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1318-9358","authenticated-orcid":false,"given":"James","family":"Dempsey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roulla","family":"Katiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Metryka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"de Kruijf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain A.","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"3581_CR1","unstructured":"Casale J, Crane JS. Biochemistry, glycosaminoglycans. In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 27, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544295\/. Accessed 29 Mar 2024."},{"issue":"457","key":"3581_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1651-2227.2008.00650.x","volume":"97","author":"W Kamin","year":"2008","unstructured":"Kamin W. Diagnosis and management of respiratory involvement in Hunter syndrome. Acta Paediatr. 2008;97(457):57\u201360. https:\/\/doi.org\/10.1111\/j.1651-2227.2008.00650.x.","journal-title":"Acta Paediatr"},{"issue":"Suppl 5","key":"3581_CR3","doi-asserted-by":"publisher","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","volume":"50","author":"J Muenzer","year":"2011","unstructured":"Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(Suppl 5):v4\u201312. https:\/\/doi.org\/10.1093\/rheumatology\/ker394.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"3581_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1136\/jmedgenet-2021-108061","volume":"59","author":"S Verheyen","year":"2022","unstructured":"Verheyen S, Blatterer J, Speicher MR, et al. Novel subtype of mucopolysaccharidosis caused by arylsulfatase K (ARSK) deficiency. J Med Genet. 2022;59(10):957\u201364. https:\/\/doi.org\/10.1136\/jmedgenet-2021-108061.","journal-title":"J Med Genet"},{"issue":"3","key":"3581_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","volume":"167","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267\u201377. https:\/\/doi.org\/10.1007\/s00431-007-0635-4.","journal-title":"Eur J Pediatr"},{"issue":"4","key":"3581_CR6","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","volume":"32","author":"SA Jones","year":"2009","unstructured":"Jones SA, Alm\u00e1ssy Z, Beck M, et al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2009;32(4):534\u201343. https:\/\/doi.org\/10.1007\/s10545-009-1119-7.","journal-title":"J Inherit Metab Dis"},{"key":"3581_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-016-0425-z","volume":"11","author":"M Rutten","year":"2016","unstructured":"Rutten M, Ciet P, van den Biggelaar R, et al. Severe tracheal and bronchial collapse in adults with type II mucopolysaccharidosis. Orphanet J Rare Dis. 2016;11:50. https:\/\/doi.org\/10.1186\/s13023-016-0425-z.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3581_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","volume":"129","author":"A Broomfield","year":"2020","unstructured":"Broomfield A, Davison J, Roberts J, et al. Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England. Mol Genet Metab. 2020;129(2):98\u2013105. https:\/\/doi.org\/10.1016\/j.ymgme.2019.07.016.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3581_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s13023-023-02805-3","volume":"18","author":"J Muenzer","year":"2023","unstructured":"Muenzer J, Burton BK, Amartino HM, et al. Neurodevelopmental status and adaptive behavior of pediatric patients with mucopolysaccharidosis II: a longitudinal observational study. Orphanet J Rare Dis. 2023;18(1):357. https:\/\/doi.org\/10.1186\/s13023-023-02805-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3581_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijporl.2014.11.014","volume":"79","author":"A Keilmann","year":"2015","unstructured":"Keilmann A, L\u00e4\u00dfig AK, Pollak-Hainz A, Mann WJ, Beck M, Hainz M. Adenoids of patients with mucopolysaccharidoses demonstrate typical alterations. Int J Pediatr Otorhinolaryngol. 2015;79(2):115\u20138. https:\/\/doi.org\/10.1016\/j.ijporl.2014.11.014.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"1","key":"3581_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/diagnostics10010037","volume":"10","author":"P Piresde Mello","year":"2020","unstructured":"Piresde Mello P, Lopes Barth A, de Araujo Torres D, Piresde Mello Valente M, Dain Gandelman Horovitz D. Laryngeal, tracheal, and bronchial disease in the mucopolysaccharidoses: endoscopic study. Diagnostics (Basel). 2020;10(1):37. https:\/\/doi.org\/10.3390\/diagnostics10010037.","journal-title":"Diagnostics (Basel)."},{"issue":"5","key":"3581_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ijporl.2005.01.017","volume":"69","author":"MA Simmons","year":"2005","unstructured":"Simmons MA, Bruce IA, Penney S, Wraith E, Rothera MP. Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2005;69(5):589\u201395. https:\/\/doi.org\/10.1016\/j.ijporl.2005.01.017.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"4","key":"3581_CR13","first-page":"267","volume":"33","author":"M Mesolella","year":"2013","unstructured":"Mesolella M, Cimmino M, Cantone E, et al. Management of otolaryngological manifestations in mucopolysaccharidoses: our experience. Acta Otorhinolaryngol Ital. 2013;33(4):267\u201372.","journal-title":"Acta Otorhinolaryngol Ital"},{"issue":"1\u20132","key":"3581_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107557","volume":"140","author":"BK Burton","year":"2023","unstructured":"Burton BK, Shively V, Quadri A, et al. Newborn screening for mucopolysaccharidosis type II: lessons learned. Mol Genet Metab. 2023;140(1\u20132): 107557. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107557.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3581_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/diagnostics11020273","volume":"11","author":"B \u00c7elik","year":"2021","unstructured":"\u00c7elik B, Tomatsu SC, Tomatsu S, Khan SA. Epidemiology of mucopolysaccharidoses update. Diagnostics (Basel). 2021;11(2):273. https:\/\/doi.org\/10.3390\/diagnostics11020273.","journal-title":"Diagnostics (Basel)"},{"issue":"11","key":"3581_CR16","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41436-020-0909-z","volume":"22","author":"KL McBride","year":"2020","unstructured":"McBride KL, Berry SA, Braverman N, ACMG Therapeutics Committee. Treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020;22(11):1735\u201342. https:\/\/doi.org\/10.1038\/s41436-020-0909-z.","journal-title":"Genet Med"},{"issue":"11","key":"3581_CR17","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/gim.2017.30","volume":"19","author":"LA Bradley","year":"2017","unstructured":"Bradley LA, Haddow HRM, Palomaki GE. Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review. Genet Med. 2017;19(11):1187\u2013201. https:\/\/doi.org\/10.1038\/gim.2017.30.","journal-title":"Genet Med"},{"issue":"4","key":"3581_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/21678707.2017.1296761","volume":"5","author":"M Stapleton","year":"2017","unstructured":"Stapleton M, Kubaski F, Mason RW, et al. Presentation and treatments for mucopolysaccharidosis type II (MPS II; Hunter Syndrome). Expert Opin Orphan Drugs. 2017;5(4):295\u2013307. https:\/\/doi.org\/10.1080\/21678707.2017.1296761.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"9683","key":"3581_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(09)60329-9","volume":"374","author":"I Chalmers","year":"2009","unstructured":"Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009;374(9683):86\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(09)60329-9.","journal-title":"Lancet"},{"issue":"Suppl 3","key":"3581_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","volume":"18","author":"PR Williamson","year":"2017","unstructured":"Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0. Trials. 2017;18(Suppl 3):280. https:\/\/doi.org\/10.1186\/s13063-017-1978-4.","journal-title":"Trials"},{"issue":"1","key":"3581_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1258\/jhsrp.2011.011131","volume":"17","author":"P Williamson","year":"2012","unstructured":"Williamson P, Altman D, Blazeby J, Clarke M, Gargon E. Driving up the quality and relevance of research through the use of agreed core outcomes. J Health Serv Res Policy. 2012;17(1):1\u20132. https:\/\/doi.org\/10.1258\/jhsrp.2011.011131.","journal-title":"J Health Serv Res Policy"},{"issue":"1","key":"3581_CR22","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1186\/s13063-021-05893-3","volume":"22","author":"AH Howie","year":"2021","unstructured":"Howie AH, Tingley K, Inbar-Feigenberg M, et al. Correction to: Establishing a core outcome set for mucopolysaccharidoses (MPS) in children: study protocol for a rapid literature review, candidate outcomes survey, and Delphi surveys. Trials. 2021;22(1):893. https:\/\/doi.org\/10.1186\/s13063-021-05893-3.","journal-title":"Trials"},{"issue":"1","key":"3581_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s13023-022-02525-0","volume":"17","author":"C von der Lippe","year":"2022","unstructured":"von der Lippe C, Neteland I, Feragen KB. Children with a rare congenital genetic disorder: a systematic review of parent experiences. Orphanet J Rare Dis. 2022;17(1):375. https:\/\/doi.org\/10.1186\/s13023-022-02525-0.","journal-title":"Orphanet J Rare Dis"},{"key":"3581_CR24","unstructured":"Soni-Jaiswal, A. A qualitative investigation of the impact of Mucopolysaccharidosis sub-types I and II on the quality of life of children and their parents. 2017. https:\/\/research.manchester.ac.uk\/en\/studentTheses\/a-qualitative-investigation-of-the-impact-of-mucopolysaccharidosi. Accessed 29 Mar 2024."},{"key":"3581_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/2326409818816721","author":"A Metryka","year":"2019","unstructured":"Metryka A, Brown N, Mercer J, et al. Toward a core outcome set for head, neck, and respiratory disease in mucopolysaccharidosis type II: systematic literature review and assessment of heterogeneity in outcome reporting. J Inborn Errors Metabol Screen. 2019. https:\/\/doi.org\/10.1177\/2326409818816721.","journal-title":"J Inborn Errors Metabol Screen"},{"key":"3581_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jclinepi.2017.12.020","volume":"96","author":"S Dodd","year":"2018","unstructured":"Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J Clin Epidemiol. 2018;96:84\u201392. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.12.020.","journal-title":"J Clin Epidemiol"},{"key":"3581_CR27","unstructured":"MPS Society. MPS Society. 2024. Available at: https:\/\/mpssociety.org.uk\/ Accessed 30 May 2024."},{"issue":"1","key":"3581_CR28","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1186\/s13063-022-06702-1","volume":"23","author":"R Katiri","year":"2022","unstructured":"Katiri R, Hall DA, Hoare DJ, et al. The Core Rehabilitation Outcome Set for Single-Sided Deafness (CROSSSD) study: international consensus on outcome measures for trials of interventions for adults with single-sided deafness. Trials. 2022;23(1):764. https:\/\/doi.org\/10.1186\/s13063-022-06702-1.","journal-title":"Trials"},{"issue":"7","key":"3581_CR29","doi-asserted-by":"publisher","first-page":"e0201378","DOI":"10.1371\/journal.pone.0201378","volume":"13","author":"DA Hall","year":"2018","unstructured":"Hall DA, Smith H, Heffernan E, Fackrell K, Core Outcome Measures in Tinnitus International Delphi (COMiT\u2019ID) Research Steering Group. Recruiting and retaining participants in e-Delphi surveys for core outcome set development: evaluating the COMiT\u2019ID study. PLoS ONE. 2018;13(7):e0201378. https:\/\/doi.org\/10.1371\/journal.pone.0201378.","journal-title":"PLoS ONE"},{"key":"3581_CR30","unstructured":"European Reference Network. European Reference Network For Hereditary Metabolic Disorders. 2021. Available at: https:\/\/metab.ern-net.eu\/. Accessed 30 May 2024."},{"issue":"1","key":"3581_CR31","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13063-018-2595-6","volume":"19","author":"AM Biggane","year":"2018","unstructured":"Biggane AM, Brading L, Ravaud P, Young B, Williamson PR. Survey indicated that core outcome set development is increasingly including patients, being conducted internationally and using Delphi surveys. Trials. 2018;19(1):430. https:\/\/doi.org\/10.1186\/s13063-018-2595-6.","journal-title":"Trials"},{"issue":"7650","key":"3581_CR32","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"key":"3581_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-016-0039-6","author":"B Young","year":"2016","unstructured":"Young B, Bagley H. Including patients in core outcome set development: issues to consider based on three workshops with around 100 international delegates. Res Involv Engagem. 2016. https:\/\/doi.org\/10.1186\/s40900-016-0039-6.","journal-title":"Res Involv Engagem"},{"issue":"8","key":"3581_CR34","doi-asserted-by":"publisher","first-page":"e1002071","DOI":"10.1371\/journal.pmed.1002071","volume":"13","author":"AG McNair","year":"2016","unstructured":"McNair AG, Whistance RN, Forsythe RO, et al. Core outcomes for colorectal cancer surgery: a consensus study. PLoS Med. 2016;13(8):e1002071. https:\/\/doi.org\/10.1371\/journal.pmed.1002071.","journal-title":"PLoS Med"},{"key":"3581_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znab192","author":"B Alkhaffaf","year":"2021","unstructured":"Alkhaffaf B, Metryka A, Blazeby JM, et al. Core outcome set for surgical trials in gastric cancer (GASTROS study): international patient and healthcare professional consensus. Br J Surg. 2021. https:\/\/doi.org\/10.1093\/bjs\/znab192.","journal-title":"Br J Surg"},{"key":"3581_CR36","unstructured":"Zoom Communications, Inc. (2024). Available at: https:\/\/www.zoom.com\/."},{"key":"3581_CR37","unstructured":"Muenzer MPS Center. UNC School of Medicine. (2024). Available at: https:\/\/www.med.unc.edu\/pediatrics\/muenzer-mps-center\/."},{"issue":"8","key":"3581_CR38","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3899\/jrheum.181097","volume":"46","author":"LJ Maxwell","year":"2019","unstructured":"Maxwell LJ, Beaton DE, Shea BJ, et al. Core domain set selection according to OMERACT filter 2.1: the OMERACT methodology. J Rheumatol. 2019;46(8):1014\u201320. https:\/\/doi.org\/10.3899\/jrheum.181097.","journal-title":"J Rheumatol"},{"key":"3581_CR39","unstructured":"Beaton D, Maxwell L ,Grosskleg S, Shea B, Tugwell P (editors). The OMERACT Handbook Version 2.1 [updated April 2021]. OMERACT. Available from https:\/\/omeract.org\/handbook\/"},{"key":"3581_CR40","doi-asserted-by":"publisher","first-page":"263300402412457","DOI":"10.1177\/26330040241245721","volume":"5","author":"AR M\u00fcller","year":"2024","unstructured":"M\u00fcller AR, van Silfhout NY, den Hollander B, et al. Navigating the outcome maze: a scoping review of outcomes and instruments in clinical trials in genetic neurodevelopmental disorders and intellectual disability. Ther Adv Rare Dis. 2024;5:26330040241245720. https:\/\/doi.org\/10.1177\/26330040241245721.","journal-title":"Ther Adv Rare Dis"},{"issue":"2","key":"3581_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/bmjebm-2022-112082","volume":"28","author":"J Hirschwald","year":"2023","unstructured":"Hirschwald J, Hofacker J, Duncan S, Walshe M. Swallowing outcomes in dysphagia interventions in Parkinson\u2019s disease: a scoping review. BMJ Evid Based Med. 2023;28(2):111\u20138. https:\/\/doi.org\/10.1136\/bmjebm-2022-112082.","journal-title":"BMJ Evid Based Med"},{"issue":"2","key":"3581_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/s0020-7489(00)00044-4","volume":"38","author":"S Keeney","year":"2001","unstructured":"Keeney S, Hasson F, McKenna HP. A critical review of the Delphi technique as a research methodology for nursing. Int J Nurs Stud. 2001;38(2):195\u2013200. https:\/\/doi.org\/10.1016\/s0020-7489(00)00044-4.","journal-title":"Int J Nurs Stud"},{"key":"3581_CR43","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org\/handbook"},{"key":"3581_CR44","doi-asserted-by":"publisher","first-page":"040223","DOI":"10.1136\/bmjopen-2020-040223","volume":"10","author":"A Lee","year":"2020","unstructured":"Lee A, Davies A, Young AE. Systematic review of international Delphi surveys for core outcome set development: representation of international patients. BMJ Open. 2020;10:040223. https:\/\/doi.org\/10.1136\/bmjopen-2020-040223.","journal-title":"BMJ Open"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03581-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T21:08:48Z","timestamp":1740604128000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03581-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3581"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03581-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was authorised by the East of England Cambridge South Research Ethics Committee (IRAS Project ID: 261752), Health Research Authority (HRA and Health and Care Research Wales (HCRW), reference: 20\/EE\/0017. Informed consent was obtained from all study participants as per the approved final study protocol, version 1.3 (30\/07\/2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was gained through informed consent gathered for all study participants as per the approved final study protocol, version 1.3 (30\/07\/2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}